AKBA - Rega marang dodolan Akebia Therapeutics Inc

Simbol lan logo merek Akebia Therapeutics Inc (AKBA)

Akebia Therapeutics (AKBA) maintains a high reputation among nephrologists due to the development of effective treatments for renal anemia. The price-to-sales valuation clearly demonstrates the capitalization dynamics relative to revenue, where the value 0.60 captures the metric level. The company is implementing oral HIF-PH inhibitors as a convenient alternative to injections, while its resilience relies on insurance coverage for its drugs and stable cash flows.

Rasio rega marang pendapatan: Akebia Therapeutics (AKBA) kanggo 04.07.2022 - 18.11.2026

Rincian analitis perusahaan Akebia Therapeutics (AKBA)

- kuotasi saiki lan rata-rata prakiraan nilai:
- statistik kapitalisasi pasar:
Analisis umum perusahaan:AKBA, Akebia Therapeutics, Inc.
Produk seri Akebia Corp

For Akebia Therapeutics (AKBA), which develops nephrology drugs through strategic alliances, the ratio of market capitalization to annual revenue determines the extent to which market expectations are inflated relative to current cash flows. An analysis of the price-to-sales ratio allows for a comparison of the business value against the actual efficiency of partnerships, where moderate values confirm the company's fundamental stability, while sharp peaks signal speculative risk.